Exelixis, Inc.'s STELLAR-303 zanzalintinib data disappoints in colorectal cancer with an FDA decision due in December 2026.
LeBron's next stop? Best offseason moves? 20 takes on a sizzling summer in the NBA After a dizzying first week of NBA free agency and a number of blockbuster trades, it's time to make some early ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results